Project Overview
This initiative will see the establishment of a translational stem cell biology team and enhancements to existing infrastructure to support functional genomics capability. This will allow for the capacity for stem cell production, organoid and cell-based disease modelling and genetic modifications for applied genomics. It will mark a significant future investment for New South Wales in clinical management and research discovery in cancers and rare genetic diseases. The initial treatment focus will be on metabolic liver disease, blinding eye disease, mitochondrial disorders, telomere and cancer disorders and cystic fibrosis.
Collaborations
- Kids Research Institute (Australia)
- City of Hope Center for Gene Technology (USA)
- Sydney Children’s Hospitals Network (Australia)
- University of Adelaide (Australia)
- Children’s Medical Research Institute (Australia)
- University of Lisbon (Portugal)
- Children’s Cancer Institute (Australia)
- University Medical Center Utrecht (Netherlands)
- Australian Functional Genomics Network (https://www.functionalgenomics.org.au/)
- Vertex Pharmaceutical
- Royal Price Alfred Hospital (Australia)
- Loxegen Pharmaceutical
- University of Technology Sydney (Australia)
- Biospecialist Ltd
- University of Sydney (Australia)
- CF Australia
